Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era-Reference-Cited by-同舟云学术

Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Era

Published:2017-09-01 Issue:9 Volume:2 Page:935
ISSN:2380-6583
Container-title:JAMA Cardiology
language:en
Short-container-title:JAMA Cardiol

Author:

Sabatine Marc S.¹,Giugliano Robert P.²

Affiliation:

1. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts2Deputy Editor, JAMA Cardiology

2. TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Cardiology and Cardiovascular Medicine

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacological therapy targeting the immune response in atherosclerosis;International Immunopharmacology;2024-11

2. PCSK9 inhibitors on the management of primary and secondary cardiovascular prevention;Lipids in Health and Disease;2024-09-10

3. Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance;Neurología (English Edition);2021-12

4. Statin-Induced Myopathy: Translational Studies from Preclinical to Clinical Evidence;International Journal of Molecular Sciences;2021-02-19

5. Inhibidores de la proproteína convertasa subtilisina/kexina tipo 9 (iPCSK9) en la prevención secundaria de episodios vasculares en pacientes con ictus isquémico: Documento de consenso y aplicaciones prácticas;Neurología;2021-01